Charles Federico, Gary Henley Join Active Implants Board

Charles W. Federico and Gary D. Henley, two heavy hitters in the orthopedic and sports medicine industries, have joined the Active Implants LLC board of managers.

“Both Charlie and Gary are respected leaders with long-term success in medical and orthopedic device industries, and they bring a wealth of strategic and operational experience to our board,” said company President and CEO Ted Davis in the July 12, 2017 news release. “We believe their diverse leadership experience will strengthen our board, and their insights will be invaluable as we continue to develop the NUsurface Meniscus Implant and fulfill a significant unmet need in the orthopedic market here in the U.S. and worldwide.”

The company wrote in the news release, “Federico has 44 years of experience in the medical device industry, with significant focus in the sports medicine segment while president and chief executive officer of Orthofix International N.V. and president of Smith & Nephew Endoscopy. Additionally, he has held senior management and sales and marketing positions with Dyonics, General Foods Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Federico has extensive board experience, including chairman of the board and lead director of MAKO Surgical Corp, sold to Stryker; and a board member at Biomimetic Therapeutics, sold to Wright Medical Group.”

“Henley has more than 35 years of experience in the orthopedic device industry, including president, chief executive officer and board member of United Orthopedic Group, which was sold to Breg. Previously, he was president and chief executive officer of Wright Medical Group, Inc.; president of Orthofix International N.V.’s Americas Division; president of Smith & Nephew’s Endoscopy Video Division; and president and chief executive officer of Cecorp, Inc. Henley is an experienced board member and industry consultant, most recently serving as executive chairman of the board of directors at OrthAlign, Inc. and a director at Orchid Orthopedic Solutions.”

Federico told OTW, “I accepted this position because I believe in the opportunity the NUsurface Meniscus implant possesses. In the first three to six months in my new role, I plan to develop working relationships with the other board members and management, as well as getting up to speed on the issues and opportunities Active Implants faces. I believe my operating and industry knowledge will help me to make a substantial contribution to the company during this important stage in its development.”

Henley commented to OTW, “I have been a fan of Active Implants’ technology for a long time and am very excited to join the company. My first few months will be focused on meeting with KOLs [key opinion leaders] to learn more about the benefits the NUsurface Meniscus Implant brings to patients, as well as understanding where the company is with regard to clinical trials and regulatory approvals. Once I have firmed up my knowledge base, I will help the team refine and execute our global go-to-market strategy. I believe the implant offers a real solution for many patients who don’t have an alternative that works, and it will be a lot of fun helping this unique technology get adopted around the world.”